MMEDMiniMed Group, Inc.

$23.31
On our screens:Stocks with no debt

The financials

MiniMed Group, Inc. by the numbers

MiniMed Group, Inc. (MMED) reported revenue of $843M in Q1 2027 (quarter ended Jul 31, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $0. For the full year FY2026, revenue was $3.10B (+14% year on year) and net income −$333M. Its largest product in Q3 2026 (quarter ended Jan 23, 2026) was Continuous Glucose Monitoring Systems CGM at $390M, 49% of the disclosed total, ahead of Consumables at 31%.

MiniMed Group, Inc. income statement, Q1 2027 against the same quarter a year earlier
Income statementQ1 2027Q1 2026Change
Revenue$843M$723M+17%
Gross profit$465M$409M+14%
Operating income$5.0M−$13Mto a profit
Net income$0−$19Mto a profit
Diluted EPS$0.00−$0.08to a profit
Revenue by product, Q3 2026 (quarter ended Jan 23, 2026), as reported to the SEC · segment disclosure runs one filing behind the income statement
ProductRevenueShare
Continuous Glucose Monitoring Systems CGM$390M49%
Consumables$244M31%
Pumps$151M19%
Product And Service Other$5.0M0.6%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q3 2026Total $790.0M (+15%)
  • Continuous Glucose Monitoring Systems CGM$390.0MQoQ +18%year on year +18%
  • Consumables$244.0MQoQ +15%year on year +15%
  • Pumps$151.0MQoQ +11%year on year +11%
  • Product And Service Other$5.0MQoQ -38%year on year -38%
Segment sum = 100% of reported consolidated revenue · Latest source: 10-K filed 2026-06-29, SEC EDGAR